Publications
Found 2 results
Author [ Title] Year Filters: Keyword is Protein Processing, Post-Translational [Clear All Filters]
E
Engineered synthetic antibodies as probes to quantify the energetic contributions of ligand binding to conformational changes in proteins.,
Mukherjee, Somnath, Griffin Dionne H., Horn James R., Rizk Shahir S., Nocula-Lugowska Malgorzata, Malmqvist Magnus, Kim Sangwoo S., and Kossiakoff Anthony A.
, J Biol Chem, 2018 02 23, Volume 293, Issue 8, p.2815-2828, (2018)
I
An improved single-chain Fab platform for efficient display and recombinant expression.,
Koerber, James T., Hornsby Michael J., and Wells James A.
, J Mol Biol, 2015 Jan 30, Volume 427, Issue 2, p.576-86, (2015)
Publications
- Characterization of synthetic antigen binding fragments targeting Toc75 for the isolation of TOC in A. thaliana and P. sativum.
- Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins.
- Development, structure, and mechanism of synthetic antibodies that target claudin and Clostridium perfringens enterotoxin complexes.
- Engineering of a synthetic antibody fragment for structural and functional studies of K+ channels.
- Isoform- and ligand-specific modulation of the adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder.
- Quaternary structure independent folding of voltage-gated ion channel pore domain subunits.
- Structural basis for assembly and lipid-mediated gating of LRRC8A:C volume-regulated anion channels.
- Structure of an AMPK complex in an inactive, ATP-bound state.
- Structure of human NTCP reveals the basis of recognition and sodium-driven transport of bile salts into the liver.
- Structure, sequon recognition and mechanism of tryptophan C-mannosyltransferase.
- Structures of ABCB4 provide insight into phosphatidylcholine translocation.
- Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias.
- Synthetic Antibodies Detect Distinct Cellular States of Chromosome Passenger Complex Proteins.
- Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.